z-logo
open-access-imgOpen Access
Discovery and Development of a Novel mPGES-1/5-LOX Dual Inhibitor LFA-9 for Prevention and Treatment of Chronic Inflammatory Diseases
Author(s) -
Nagendra Sastri Yarla,
Gopal Pathuri,
Hariprasad Gali,
Simon Terzyan,
Janani Panneerselvam,
Parthasarathy Chandrakesan,
Marcus Tullius Scotti,
Courtney W. Houchen,
Venkateshwar Madka,
Chinthalapally V. Rao
Publication year - 2020
Publication title -
journal of inflammation research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.656
H-Index - 33
ISSN - 1178-7031
DOI - 10.2147/jir.s286110
Subject(s) - pharmacology , cyclooxygenase , arachidonate 5 lipoxygenase , prostaglandin e2 , inflammation , chemistry , medicine , immunology , enzyme , biochemistry , arachidonic acid
Non-steroidal anti-inflammatory drugs, cyclooxygenase (COX)-2 selective inhibitors, have been explored for prevention and treatment of several inflammatory chronic conditions including arthritis, and cancer. However, the long-term use of these drugs is associated with gastrointestinal, renal, and cardiovascular side effects. Later, COX/5-lipoxygenase (5-LOX) dual inhibitors (eg, licofelone) have been developed but did not enter into the market from the clinical trails due to COX-1/2 inhibition-associated side effects. Hence, targeting microsomal prostaglandin E synthase-1 (mPGES-1) and 5-LOX can be an ideal approach while sparing COX-1/2 activities for development of the next generation of anti-inflammatory drugs with better efficacy and safety.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here